Meliodays Medical has entered into a partnership with Celanese Corporation for the preclinical development of MelioOne, the first non-contraceptive, hormone-free IUD specifically designed to relieve menstrual pain. With MelioOne, the Munich-based startup is developing an IUD that delivers a local painkiller instead of hormones.
MelioOne combines an innovative medical device design with a non-hormonal drug delivery system and Celanese's VitalDose drug delivery platform. This platform enables reliable and localized drug delivery that directly targets the source of pain, avoiding systemic side effects commonly associated with oral pain medications.
Revolutionizing the treatment of menstrual pain
Simone Sabbione, CEO and co-founder of Meliodays, explains:
"More than 80 percent of menstruating people suffer from period pain and cramps. Our partnership with Celanese is the first milestone toward our goal of revolutionizing the treatment of menstrual pain. Our localized delivery targets the source of pain and avoids systemic side effects often associated with oral pain medications. Given the significant impact menstrual pain has on people's professional, school, and social lives, we are pleased to be working with Celanese to lead the way in enabling menstruating people to enjoy a natural, uninterrupted cycle."
With this approach, Meliodays addresses an area of high unmet medical need. The goal: effective treatment of period pain without the need for hormones or systemic painkillers.
Celanese contributes proven platform technology
Celanese's VitalDose Drug Delivery Platform has been used in approved pharmaceuticals in the US and Europe for over two decades, particularly in patient-centric applications in women's health. The technology is suitable for the controlled release of various drug types and is used in a wide variety of dosage forms.
“We are pleased to be working with Meliodays in the early development of their IUD, with the hope that it will eventually be prescribed by healthcare professionals to relieve women of menstrual pain,”
says Brian Duke, Sr. Marketing Manager Pharmaceutical Solutions Celanese.
"Our Celanese team is proud that the VitalDose Drug Delivery Platform has been used for so long in patient-focused therapies to provide women with a convenient and effective treatment. We will continue to advance its application in therapies for women and anywhere where sustained drug delivery offers benefits."
With MelioOne, Meliodays aims to provide menstruating women with pain-free periods without disrupting their natural cycle. The collaboration with Celanese represents an important step in the further development of the product toward a marketable therapy.
